Allergic bronchopulmonary aspergillosis (ABPA) is an inflammatory disease caused by immunologic reactions initiated against Aspergillus fumigatus colonizing the airways of patients with asthma and cystic fibrosis. The common manifestations include treatment-resistant asthma, transient and fleeting pulmonary opacities and bronchiectasis. It is believed that globally there are about five million cases of ABPA, with India alone accounting for about 1.4 million cases. The occurrence of ABPA among asthmatic patients in special clinics may be as high as 13 per cent. Thus, a high degree of suspicion for ABPA should be entertained while treating a patient with bronchial asthma, particularly in specialized clinics. Early diagnosis and appropriate treatment can delay (or even prevent) the onset of bronchiectasis, which suggests that all patients of bronchial asthma should be screened for ABPA, especially in chest clinics. The current review summarizes the recent advances in the pathogenesis, diagnosis and management of ABPA.


中文翻译：

---

过敏性支气管肺曲菌病。


过敏性支气管肺曲霉病（ABPA）是一种由针对烟曲霉的免疫反应引起的炎性疾病在哮喘和囊性纤维化患者的气道中定植。常见表现包括抗药性哮喘，短暂而短暂的肺部混浊和支气管扩张。据信，全球约有500万例ABPA病例，仅印度就占约140万例。在特殊诊所中，哮喘患者中ABPA的发生率可能高达13％。因此，在治疗支气管哮喘患者时，尤其是在专门诊所中，应高度怀疑ABPA。早期诊断和适当的治疗可能会延迟（甚至预防）支气管扩张的发作，这表明应该对所有支气管哮喘患者进行ABPA筛查，尤其是在胸部诊所。本综述总结了发病机理的最新进展，